MyeloidScan [COVID-19]
Research type
Research Study
Full title
MyeloidScan – A longitudinal observational cohort study investigating the impact of COVID 19 infection on organ function in patients with myeloid blood cancers
IRAS ID
292188
Contact name
Onima Chowdhury
Contact email
Sponsor organisation
Oxford University Hospital NHS Trust
Duration of Study in the UK
2 years, 6 months, 1 days
Research summary
Around 250, 0000 people are living in the UK with a blood cancer. Blood cancers can be divided into more specific subgroups. The chronic myeloid blood cancers are a group of blood cancers which result in increased infections, anaemia, problems with the blood clotting system and progression to acute leukaemia.
Myeloid blood cancer patients have been shown to be at greater risk of severe covid 19 infection and death. One reason may be that myeloid blood cancer patients have less immunity to infections and their body organs are already under strain, due to the cancer and the drugs we use to treat it. It also seems that large numbers of non-cancer patients that have had Covid 19 infection, go on to develop more long term problems known as "Long Covid" but we don’t know if this affects patients with blood cancers too. There is also recent news of effective covid 19 vaccines but we know from previous studies of different vaccines, that patients with blood cancer often do not respond as well as the general public do to vaccinations.
In this study, we will look at the body using MRI scans and the immune system using blood tests, to map the impact of Covid 19 infection and vaccination on organ health in patients with blood cancer. This study aims to measure organ damage in lungs, heart, kidney, liver, pancreas, spleen as assessed by MRI. Participants will be invited to an imaging center where they will have blood tests and an MRI scan at trial entry, 6 months and then 12 months later. The study will last 24 months including 12 months follow up. All participants will receive standard-of-care by their healthcare team. Assessing the sequelae of COVID-19 in patients is crucial to enable planning for health-care needs.
REC name
West Midlands - Black Country Research Ethics Committee
REC reference
21/WM/0067
Date of REC Opinion
5 Mar 2021
REC opinion
Further Information Favourable Opinion